Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

20.29 +0.40 (+2.01%)
Streaming Delayed Price Updated: 12:49 PM EDT, Mar 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics’ Rights Offering Nearing Expiration Date
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Summit Therapeutics Inc.
Via Business Wire
Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals’ Ibezapolstat Takes Center Stage After Summit Therapeutics Misses Phase 3 C.Diff Trial Endpoints (NASDAQ: ACXP)
Via AB Newswire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
AcurX Pharmaceuticals’ C. Difficile Drug Candidate Could Fetch $800 Million On A Peer Comparison Basis (NASDAQ: ACXP)
Via AB Newswire
Exposures Product Safety
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.